European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 143, Issue 2 , Pages 69-74, April 2009

Gynecologic Cancer Intergroup (GCIG) proposals for changes of the current FIGO staging system

  • Edgar Petru

      Affiliations

    • Department of Obstetrics and Gynecology, Medical University of Graz, Auenbruggerplatz 14, A-8036 Graz, Austria
    • On behalf of the GCIG FIGO Working Group.
    • Corresponding Author InformationCorresponding author. Tel.: +43 316 385 81082; fax: +43 316 385 2546.
  • ,
  • Hans-Joachim Lück

      Affiliations

    • Department of Gynecology and Gynecologic Oncology, Horst Schmidt Kliniken, Wiesbaden, Germany
    • On behalf of the GCIG FIGO Working Group.
  • ,
  • Gavin Stuart

      Affiliations

    • Department of Gynecologic Oncology, University of British Columbia, BC, USA
    • On behalf of the GCIG FIGO Working Group.
  • ,
  • David Gaffney

      Affiliations

    • Department of Radiation Oncology, Huntsman Cancer Institute, University of Utah, UT, USA
    • On behalf of the GCIG FIGO Working Group.
  • ,
  • David Millan

      Affiliations

    • Department of Pathology, University of Glasgow, Glasgow, United Kingdom
    • On behalf of the GCIG FIGO Working Group.
  • ,
  • Ignace Vergote

      Affiliations

    • Department of Gynecologic Oncology, Catholic University Hospital Leuven, Leuven, Belgium
    • On behalf of the GCIG FIGO Working Group.

Received 10 May 2008; received in revised form 25 November 2008; accepted 22 December 2008. published online 27 January 2009.

Abstract 

The FIGO has invited the GCIG to make contributions for possible changes of the FIGO staging system. We report on the consensus within the GCIG committee to propose the following changes in the current FIGO classification. Cervical cancer: Since fertility-preserving surgery is increasingly used in early disease, stage IB1-A may include tumors of up to 2cm in diameter. Endometrial cancer: Positive peritoneal cytology alone should not classify this patient to be allotted to stage IIIA disease. Lymphadenectomy should be recommended in high-risk clinical stage I patients and in those with adverse histologies. Ovarian cancer: In early stage disease, grading and in advanced disease, the amount of residual disease should be reported. Vulvar cancer: The lymph node status should always be reported. In the case of enlarged inguinal nodes, histology should be obtained by any means. Vaginal cancer: Besides bladder and rectal tumor involvement urethral mucosal involvement should be added. Gestational trophoblastic disease: The modified WHO scoring system which is widely accepted should be adopted.

Keywords: FIGO staging, FIGO classification, Ovarian cancer, Cervical cancer, Vulvar cancer

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0301-2115(09)00010-4

doi:10.1016/j.ejogrb.2008.12.015

European Journal of Obstetrics & Gynecology and Reproductive Biology
Volume 143, Issue 2 , Pages 69-74, April 2009